A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
A phase 2 trial of Tucatinib, Trastuzumab and Capecitabine in advanced solid tumours, run by Pfizer, active and no longer recruiting.
Overview
A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) is a phase 2 interventional study registered as NCT04721977 by Pfizer, with 66 participants enrolled, started 2021-04-08 and due to reach its primary completion in 2023-07-17. Interventions recorded: Tucatinib, Trastuzumab and Capecitabine. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialTucatinib+Trastuzumab+Eribulin in HER2+ MBC
Shares Tucatinib, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of DB-1310 in Advanced/Metastatic Solid Tumors
Shares Capecitabine, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Shares Capecitabine, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSafety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
Shares Capecitabine, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.